Wayfinder Medical
Wayfinder Medical
Navigate what comes next
CONDITION GUIDE

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Medical Overview

CIDP is an immune-mediated disorder that attacks the peripheral nerves. Your immune system mistakenly targets the myelin sheath -- the protective insulation around nerve fibers -- causing inflammation, demyelination, and progressive weakness and sensory loss. It is the chronic counterpart to Guillain-Barre syndrome (GBS), but unlike GBS, CIDP develops slowly over at least 8 weeks and can persist for months, years, or indefinitely.

CIDP affects males more than females at roughly a 2:1 ratio. Overall prevalence ranges from 0.8 to 8.9 per 100,000 people, with an increased incidence in older adults. The mean age at diagnosis is around 60, though it can occur in children. Juvenile cases are more likely to present with a relapsing course.

What happens in CIDP:

Your immune system -- through both T-cells and antibodies -- attacks the myelin covering of peripheral nerves, particularly near the nodes of Ranvier (gaps in the myelin sheath where nerve signals are transmitted). This strips away or damages the myelin, slowing or blocking nerve signal transmission. Over time, the underlying nerve fibers (axons) can also be damaged as a secondary effect.

About 10% of patients have identifiable autoantibodies targeting specific proteins at the nerve nodes, including neurofascin-155, neurofascin-186, and contactin-1. These antibody-positive variants may behave differently and respond differently to treatment.

Typical CIDP presents with: About 50-60% of cases follow the typical pattern. The rest present as atypical variants: sensory-predominant, motor-predominant, asymmetric (Lewis-Sumner syndrome), or distal (DADS neuropathy).

CIDP can be monophasic (one episode that resolves), relapsing-remitting, or chronically progressive. About one-third of patients have a relapsing-remitting course.

Most cases are idiopathic -- no identifiable trigger. Some cases are associated with other conditions including lupus, HIV, hepatitis B or C, or diabetes.

Diagnosis & Treatment

Getting Diagnosed

CIDP is frequently misdiagnosed or delayed in diagnosis. The diverse presentations and the lack of a single definitive test make it challenging. Overdiagnosis is also a real problem -- some patients are treated for CIDP when they actually have a different condition.

Diagnostic criteria require: Key diagnostic tests:

Treatment

CIDP is treatable. Unlike many neurological conditions on this site, CIDP often responds well to treatment, and many people achieve significant improvement. That said, treatment is typically long-term and carries its own burdens.

First-line treatments: Second-line treatments (when first-line fails or for maintenance): Managing treatment:

Treatment often needs to continue long-term to prevent relapse. Finding the minimum effective dose and frequency is a process of trial and adjustment. Some patients achieve remission and can stop treatment. Others need ongoing maintenance indefinitely.

Physical and occupational therapy are important complements to medical treatment, helping maintain strength, mobility, and function.

Accommodation Strategies

CIDP causes fluctuating weakness, sensory loss, fatigue, and balance problems. Accommodations need to account for the unpredictable nature of the condition and the demands of ongoing treatment (infusions, medical appointments).

Workplace accommodations:

Benefits & Disability

Social Security Disability (SSDI/SSI)

The SSA evaluates CIDP under Listing 11.14 -- Peripheral neuropathy, which requires disorganization of motor function in two extremities resulting in extreme limitation in standing, balancing, walking, or using upper extremities.

CIDP may also be evaluated under listings for autoimmune disorders if it occurs alongside other immune conditions.

If you do not meet a specific listing, an RFC assessment can document how your combination of weakness, sensory loss, fatigue, treatment side effects, and treatment schedule prevents you from maintaining full-time employment.

Documentation strategy: Nerve conduction study results showing demyelination, treatment records including frequency and response, physical therapy evaluations documenting functional limitations, and physician statements about what you can and cannot do physically. Document treatment side effects and the time burden of infusions.

Workers' Compensation

CIDP is an autoimmune condition, so workers' comp does not cover the disease itself. However, if CIDP was triggered by a workplace exposure or infection, or if workplace conditions significantly worsen your symptoms, there may be a compensable claim depending on your state.

Notable Public Figures

CIDP does not have widely recognized public figures associated with it. The condition is rare enough that most people -- including many doctors -- have never heard of it.

The absence of public representation is part of the experience. Explaining your condition to friends, employers, and even medical professionals who are unfamiliar with it is a recurring burden. Patient advocates within the CIDP community have worked to increase visibility, but the condition remains largely unknown outside of neurology.

Newly Diagnosed

If you just received a CIDP diagnosis, here is what you need to know.

This is treatable. Unlike many conditions in this encyclopedia, CIDP responds to treatment in most cases. This does not mean it is simple or easy, but it means that effective options exist. Treatment is a process. Finding the right treatment, the right dose, and the right schedule takes time. Some people respond quickly. Others need to try multiple approaches. Do not lose hope if the first treatment does not work well. Get to a neuromuscular specialist. CIDP is complex enough that a general neurologist may not have extensive experience with it. A neuromuscular specialist or a center with a peripheral neuropathy program will provide the most informed care. IVIG is not a cure. It manages the condition. Many people need ongoing infusions to maintain function. If you stop treatment, symptoms may return. This is normal and does not mean the treatment is failing. Watch for overdiagnosis. CIDP can be overdiagnosed. If treatment is not working at all, it is worth questioning whether the diagnosis is correct. Nerve conduction studies should show clear evidence of demyelination. Fatigue is real. CIDP fatigue goes beyond normal tiredness. It is a direct effect of the disease and the treatment. Plan your energy accordingly and do not expect yourself to function at pre-illness levels. Connect with others. The GBS-CIDP Foundation International (gbs-cidp.org) connects patients, funds research, and provides educational resources. Online support groups exist on Facebook and other platforms.

Culture & Media

CIDP is virtually absent from mainstream media. No films, television shows, or major cultural works feature the condition. It exists in the gap between conditions common enough to be recognized (like multiple sclerosis, which shares some similarities) and conditions rare enough to generate "rare disease" media interest.

Within the neurology community, CIDP is well-recognized and actively researched. Outside of it, the condition is largely unknown. Patient advocacy organizations have worked to bridge this gap, but progress has been slow.

The invisible nature of the condition compounds this. People with CIDP often look healthy, which makes explaining the severity of their symptoms to others an ongoing challenge.

Creators & Resources

Organizations

Support Communities

Medical Resources

Key Statistics